THIS SITE IS INTENDED FOR UK AND IRELAND HEALTH PROFESSIONALS ONLY
CREATED BY LEO PHARMA

Efficacy

Raising the bar in topical treatment:
the clinical data

Enstilar® is more effective than its individual active components in achieving plaque clearance at week 41

Proportion of patients achieving treatment success* at week 4 on trunk and limbs with Enstilar® vs. individual mono components1

Enstilar® is more effective than calcipotriol betamethasone ointment in achieving plaque clearance over the recommended
4 week treatment course2

More than half of Enstilar® patients achieved treatment success** at week 42

*A randomised, double-blind, multicentre, three-arm, Phase II study. Treatment success of body psoriasis according to PGA at Week 4, defined as clear or almost clear from baseline for patients with moderate/severe disease and clear from baseline for those with mild disease.1

**A Phase II, multicentre, investigator-blinded study. Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement according to the PGA.2
CI, confidence interval; OR, odds ratio; PGA, physician’s global assessment.

References
  1. Lebwohl M et al. J Clin Aesthet Dermatol 2016;9(2):34–41.
  2. Koo J et al. J Dermatolog Treat 2016; 27(2):120–127.

UK/IE MAT-04319 V4
Date of preparation: September 2018